UBS Maintains Buy on AdaptHealth, Lowers Price Target to $10
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $10.
Read original at benzingaStocks · News reference
AdaptHealth Divests Diabetes Health Business To Cardinal Health For $235M In Cash
Continues the Company's multi-year effort to focus its portfolio on its core sleep, respiratory, and supporting home medical equipment businessesSharpens strategic focus on businesses where the Company crosses the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 8:31 PM
- Checked
- Jul 20, 2026, 8:31 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
RBC Capital Maintains Outperform on AdaptHealth, Lowers Price Target to $8
RBC Capital analyst Ben Hendrix maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and lowers the price target from $15 to $8.
Read original at benzingaTruist Securities Maintains Buy on AdaptHealth, Lowers Price Target to $9
Truist Securities analyst David Macdonald maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $9.
Read original at benzingaCrude Oil Down Over 5%; McDonald's Earnings Top Views
U.S. stocks gain with Nasdaq up more than 2% on Tuesday. Dow up 1.79% to 54,129.35, Nasdaq up 2.22% to 26,490.24, S&P 500 up 1.64% to 7,725.48. Tech shares jump 3.8%, utilities down 0.5%. McDonald's beats earnings estimates. Ibotta, Backblaze, Corvex up, Adapthealth, Better Home & Finance, Clearpoint Neuro down.
Read original at benzingaCardinal Health's CFO Moved $9.9 Million of Stock. Here's What Long-Term Investors Should Know
Cardinal Health's CFO Aaron Alt sold 42,000 shares worth $9.9 million on August 18, reducing his direct holdings to 20,495 shares. The sale occurred after the stock surged 57% over the past year. Despite the insider sale, the company maintains strong guidance with fiscal 2027 EPS projected at $12.40-$12.60 (13-15% growth), planned capital expenditures of $700 million, and at least $1 billion in share repurchases expected.
Read original at the-motley-foolRBC Capital Initiates Coverage On Cardinal Health with Outperform Rating, Announces Price Target of $276
RBC Capital analyst Ryan Halsted initiates coverage on Cardinal Health (NYSE:CAH) with a Outperform rating and announces Price Target of $276.
Read original at benzinga